Rallybio Statistics
Total Valuation
Rallybio has a market cap or net worth of $84.64 million. The enterprise value is -$6.06 million.
| Market Cap | 84.64M |
| Enterprise Value | -6.06M |
Important Dates
The last earnings date was Tuesday, October 27, 2026, before market open.
| Earnings Date | Oct 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Rallybio has 5.38 million shares outstanding. The number of shares has increased by 2.81% in one year.
| Current Share Class | 5.38M |
| Shares Outstanding | 5.38M |
| Shares Change (YoY) | +2.81% |
| Shares Change (QoQ) | -1.43% |
| Owned by Insiders (%) | 22.35% |
| Owned by Institutions (%) | 36.80% |
| Float | 1.64M |
Valuation Ratios
The trailing PE ratio is 3.38.
| PE Ratio | 3.38 |
| Forward PE | n/a |
| PS Ratio | 195.01 |
| Forward PS | n/a |
| PB Ratio | 0.91 |
| P/TBV Ratio | 0.92 |
| P/FCF Ratio | 2.73 |
| P/OCF Ratio | 2.73 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 28.87, with zero debt.
| Current Ratio | 28.87 |
| Quick Ratio | 27.63 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 34.52% and return on invested capital (ROIC) is -17.62%.
| Return on Equity (ROE) | 34.52% |
| Return on Assets (ROA) | -16.79% |
| Return on Invested Capital (ROIC) | -17.62% |
| Return on Capital Employed (ROCE) | -23.75% |
| Weighted Average Cost of Capital (WACC) | 0.02% |
| Revenue Per Employee | $72,333 |
| Profits Per Employee | $4.47M |
| Employee Count | 6 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Rallybio has paid $1.40 million in taxes.
| Income Tax | 1.40M |
| Effective Tax Rate | 4.98% |
Stock Price Statistics
The stock price has increased by +181.42% in the last 52 weeks. The beta is -0.77, so Rallybio's price volatility has been lower than the market average.
| Beta (5Y) | -0.77 |
| 52-Week Price Change | +181.42% |
| 50-Day Moving Average | 16.52 |
| 200-Day Moving Average | 13.45 |
| Relative Strength Index (RSI) | 41.18 |
| Average Volume (20 Days) | 36,009 |
Short Selling Information
The latest short interest is 39,026, so 0.72% of the outstanding shares have been sold short.
| Short Interest | 39,026 |
| Short Previous Month | 40,962 |
| Short % of Shares Out | 0.72% |
| Short % of Float | 2.38% |
| Short Ratio (days to cover) | 2.05 |
Income Statement
In the last 12 months, Rallybio had revenue of $434,000 and earned $26.81 million in profits. Earnings per share was $4.65.
| Revenue | 434,000 |
| Gross Profit | -5.83M |
| Operating Income | -21.92M |
| Pretax Income | 28.21M |
| Net Income | 26.81M |
| EBITDA | -21.91M |
| EBIT | -21.92M |
| Earnings Per Share (EPS) | $4.65 |
Balance Sheet
The company has $90.69 million in cash and no debt, with a net cash position of $90.69 million or $16.85 per share.
| Cash & Cash Equivalents | 90.69M |
| Total Debt | n/a |
| Net Cash | 90.69M |
| Net Cash Per Share | $16.85 |
| Equity (Book Value) | 92.30M |
| Book Value Per Share | 17.31 |
| Working Capital | 91.49M |
Cash Flow
| Operating Cash Flow | 30.99M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 8,000 |
| Net Borrowing | n/a |
| Free Cash Flow | 30.99M |
| FCF Per Share | $5.76 |
Margins
| Gross Margin | n/a |
| Operating Margin | -5,050.92% |
| Pretax Margin | 6,500.92% |
| Profit Margin | 6,177.42% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | 7,139.63% |
Dividends & Yields
Rallybio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -2.81% |
| Shareholder Yield | -2.81% |
| Earnings Yield | 29.60% |
| FCF Yield | 36.61% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
The last stock split was on February 6, 2026. It was a reverse split with a ratio of 1:8.
| Last Split Date | Feb 6, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:8 |
Scores
Rallybio has an Altman Z-Score of 6.48 and a Piotroski F-Score of 5.
| Altman Z-Score | 6.48 |
| Piotroski F-Score | 5 |